account_id none on file
legal_name Supernus Pharmaceuticals, Inc.
ticker SUPN
cik 1356576
domain supernus.com
linkedin_company_url https://www.linkedin.com/company/supernus-pharmaceuticals/
entry_point_account_id none on file
name Supernus Pharmaceuticals Inc.
exchange Nasdaq
sector Health Care
hq Rockville, MD, United States
sector index/company/sector/health-care/
calls 1 filings 0 executives 3 family 0
why_nownone on file
calls
The FDA mentioned that approval of the NDA requires inspections that could not be completed in a timely manner due to COVID-19 travel restrictions.
Nov 8, 2022 / receipt, needs a key / Jack Katar, CEO | earnings call 2022-11-08 | transcript bf02d686-47ce-4d4a-9306-955b0d60b417 | chars 5606-5753 | segment 5
filingsnone on file
executives
| Charles W. Newhall | Chairman | - | receipt |
| Jack Katar | CEO | - | receipt |
| Tim Deck | Chief Financial Officer | - | receipt |
familynone on file
upcoming
changes
| 2016-08-12 | Chairman, appointed | sec_8k |
mcp_package_hint
slug supernus-pharmaceuticals-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$